Silence Therapeutics amends 8-K to disclose $1.28 million separation benefits for ex-CFO Tooman

SLN•2026-07-16

Separation benefits disclosed in amended 8-K

Silence Therapeutics filed an amended Form 8-K to update executive-compensation disclosure tied to former CFO Craig Tooman’s December 14, 2025 departure.

The July 10, 2026 separation agreement sets cash benefits of $1.28 million, including $655,000 salary continuation and a $250,000 severance payment.

It also provides a $283,746.03 bonus payment, $46,896.48 healthcare premium reimbursement, $40,000 legal-fee reimbursement, and up to $20,000 for tax-provider fees.

Equity terms include limited continued vesting, longer option exercise windows, and potential vesting acceleration on a change of control within 12 months.

Sources

Silence Therapeutics amends 8-K to disclose $1.28 million separation benefits for ex-CFO Tooman

Sec

Silence Therapeutics amends 8-K to disclose $1.28 million separation benefits for ex-CFO Tooman

Separation benefits disclosed in amended 8-K

Related News

Bone Biologics delays annual shareholder meeting to Sept. 28 from Aug. 11

FormFactor CEO Mike Slessor sells 4,735 shares worth $559,508.33

La Rosa Holdings corrects 8-K date for Series E preferred stock filing to July 9, 2026

Sources

Silence Therapeutics amends 8-K to disclose $1.28 million separation benefits for ex-CFO Tooman

Elutia Signs Definitive Agreement To Sell Simpliderm in Transaction Valued At Up To $11 Million, Strengthening Balance Sheet Ahead Of NXT-41X Launch

Red Cat CEO, Chairman Jeffrey M. Thompson sells 150,000 shares for $1.28 million